Evidence map›Paper›PMID 39569692›Full record

ArticleEuropean journal of neurology2025

Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: A French cohort study.

Luce Barbat du Closel, Nathalie Bonello-Palot, Emilien Delmont, Yann Péréon, Andoni Echaniz-Laguna, Jean Philippe Camdessanché, Aleksandra Nadaj Pakleza, Jean-Baptiste Chanson, Simon Frachet, Laurent Magy and 12 more

Abstract read
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Luce Barbat du CloselReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.ORCID 0000-0002-4422-1425
Nathalie Bonello-PalotMarseille Medical Genetics, Aix-Marseille University-Inserm UMR 1251, Marseille, France.ORCID 0000-0002-8657-1271
Emilien DelmontReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.ORCID 0000-0002-5591-2774
Yann PéréonCHU Nantes, Laboratoire d'Explorations Fonctionnelles, Reference Center for NMD AOC, Filnemus, Euro-NMD, Nantes, France.
Andoni Echaniz-LagunaDepartment of Neurology, APHP, CHU de Bicêtre, Le Kremlin-Bicêtre, France.ORCID 0000-0003-1012-9783
Jean Philippe CamdessanchéDepartment of Neurology and Reference Centre for Neuromuscular Diseases, Saint Etienne, France.ORCID 0000-0002-5282-6707
Aleksandra Nadaj PaklezaCentre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Jean-Baptiste ChansonCentre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.ORCID 0000-0003-4221-3840
Simon FrachetService et Laboratoire de Neurologie, Centre de Référence Neuropathies Périphériques rares, NNerf, UR NeurIT, CHU Limoges, Limoges, France.
Laurent MagyService et Laboratoire de Neurologie, Centre de Référence Neuropathies Périphériques rares, NNerf, UR NeurIT, CHU Limoges, Limoges, France.
Julien CassereauReference Center for Neuromuscular Disorders AOC and National Reference Center for Neurogenetic Diseases, Angers University Hospital, Angers, France.ORCID 0000-0002-1656-552X
Pascal CintasCentre de référence de pathologie neuromusculaire de Toulouse. Hôpital Purpan, Toulouse, France.
Ariane ChoumertService des Maladies Neurologiques Rares, CHU de la Réunion-GH Sud Réunion-Saint-Pierre, Marseille, France.ORCID 0000-0001-6476-362X
Perrine DevicDepartment of Neurology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Sarah Léonard LouisAPHP, Centre de référence des maladies neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France.
Céline TardU1172, centre de référence des maladies neuromusculaires Nord/Est/Ile-de-France, CHU de Lille, Lille, France.
Guilhem SoléCentre de référence des maladies neuromusculaires AOC CHU de Bordeaux Hôpital Pellegrin, Bordeaux, France.
Emmanuelle Salort-CampanaReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.
Françoise BouhourService d'Electroneuromyographie et Pathologies Neuromusculaires, Hospices Civils de Lyon, Lyon, France.
Philippe LatourPGNM, Institut NeuroMyoGène, Université Lyon1-CNRS UMR5261-INSERM, Lyon, France.
Tanya StojkovicAPHP, Centre de référence des maladies neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France.
Shahram AttarianReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeX-linked Charcot-Marie-Tooth disease type 1 (CMTX1) ranks as the second most prevalent hereditary neuropathy and, currently, has no definitive cure. Emerging preclinical trials offer hope for potential clinical studies in the near future. While it is widely accepted that experimental groups in these trials should be balanced for age and gender, there is a current shortfall in data regarding phenotype-genotype correlations. Our aim was to provide a more detailed understanding of these correlations to facilitate the formation of well-matched patient groups in upcoming clinical trials.

methodsWe conducted a retrospective evaluation of CMTX1 patients from 13 designated reference centers in France. Data on genetics, clinical features, and nerve conduction were systematically gathered.

resultsWe analyzed the genotype-phenotype correlations in 275 CMTX1 patients belonging to 162 families and carrying 87 distinct variants. Patients with variants affecting the transmembrane domains demonstrated significantly greater severity, as evidenced by a Charcot-Marie-Tooth Examination Score of 10.5, compared to 7.1 for those with intracellular domain variants and 8.7 for extracellular domain variants (p < 0.000). These patients also experienced an earlier age of onset, showed slower ulnar nerve conduction velocities and had more substantial loss of motor amplitude.

conclusionsThis study confirms the presence of a correlation between the mutated protein domain and the clinical phenotype. Patients with a variant in the transmembrane domains demonstrated a more severe clinical and electrophysiological profile. Consequently, the genotype could play a prognostic role in addition to its diagnostic role, and it will be essential to consider this in future clinical trials.

Indexed as

Charcot-Marie-Tooth DiseaseGenetic Association StudiesAdolescentAdultAgedChildChild, PreschoolCohort StudiesFemaleFranceGenotypeHumansMaleMiddle AgedMutationNeural ConductionCharcot‐Marie‐Toothclinical trialCMTXconnexine 32hereditary peripheral neuropathy

Identifiers

PMID39569692
PMCPMC11622270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.